Wortmannin

For research use only.

Catalog No.S2758 Synonyms: KY 12420

202 publications

Wortmannin Chemical Structure

CAS No. 19545-26-7

Wortmannin (KY 12420) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 172 In stock
EUR 108 In stock
EUR 223 In stock
EUR 439 In stock
EUR 2230 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Wortmannin has been cited by 202 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin (KY 12420) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 NInCepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrzZVBCOi53IN88US=> NYDzW40xOS12IHS= MXXEUXNQ M13s[YVvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25idILlZZRu\W62IIfpeIghfGGvb4jp[oVv MYqyOVQ6ODN6Mx?=
H1703 NFTYXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmizNk42KM7:TR?= NUm2RYNiOS12IHS= MXLEUXNQ MVjlcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKHS{ZXH0cYVvfCC5aYToJJRidW:6aX\lci=> MkPENlU1QTB|OEO=
HUVECs NXHxdXVuS3m2b4TvfIlkcXS7IFHzd4F6 NYTR[456OTByIH7N NHzoSmQzPCCq MlG4ZZR1\W63YYTld{B1cGViYXLyc4difGm4ZTDl[oZm[3S|IH;mJINidHmlb4PpckBwdiCYUlmtbY5lfWOnZDDjfZRwfG:6aXPpeJk> MVmyOVQ2ODF6Nh?=
APRE-19 MUXBdI9xfG:|aYOgRZN{[Xl? NF[5VYs2KM7:TR?= NVzKO4JtOjRiaB?= MkXCZYJwdGm|aHXzJGZNYi2vZXTpZZRm\CCycn:td5Vzfmm4YXyvZY51cS2jcH;weI9{cXNiYXP0bZZqfHl? NX:3XmdPOjV|Mkm2NVc>
MDA-MB-231 MonORZBweHSxc3nzJGF{e2G7 Mn7iNeKh|ryPwrC= NEP4bo01QCCq MVfEUXNQ M1ThNoRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEB1emWjdHXkJJdqfGhiMkWg{txOKG:oIF[xJI9zKEZ{INMg MYSyOVMxODl|Mh?=
MCF7 MlPZSpVv[3Srb36gRZN{[Xl? M4\6T|ExOCCwTR?= MnvTNlQhcA>? NWP3VmJy\WyrbXnuZZRmeyCHMj3pcoR2[2WmIFHSSU1NfWNiYXP0bZZqfHl? MUKyOVE4OjV3Nx?=
HT-29  NHXjdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK1OJMyNjYEoNM1US=> NInsd|M6PiCq MUfk[YNz\WG|ZYOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIHnubIljcXSnZDDifUBMYU6D NWXFVY1tOjVyMUKxNlM>
MO59K  MofmR5l1d3SxeHnjbZR6KEG|c3H5 NFXKbIc2yqEQvF2= M2TuW|ch\A>? M{XVO2ROW09? M1nONYVvcGGwY3XzJJRp\SCleYTveI95cWOrdImgc4Yh\XSxcH;zbYRmKG:{IHPpd5Bt[XSrbh?= Ml35NlQ6PTN3NkG=
MO59J NE[2WnlEgXSxdH;4bYNqfHliQYPzZZk> NGXSZos2yqEQvF2= NXTnU3ZuPyCm NF\3T3BFVVOR NWLCWFg2\W6qYX7j[ZMhfGinIHP5eI91d3irY3n0fUBw\iCndH;wc5Nq\GVib4KgZ4l{eGyjdHnu NHnKb2szPDl3M{W2NS=>
MO59K  NY[0cnY3SXCxcITvd4l{KEG|c3H5 NYjGXlJoOTBizszN MUSyOEBp MmLkSG1UVw>? NGXhR5pqdmO{ZXHz[ZMhfGinIFTTRkBt\X[nbDDpcoR2[2WmIHL5JIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? M1r5[FI1QTV|NU[x
MO59J MX;BdI9xfG:|aYOgRZN{[Xl? NEWwcnEyOCEQvF2= NFm5OHczPCCq MkH4SG1UVw>? NISwSoRqdmO{ZXHz[ZMhfGinIFTTRkBt\X[nbDDpcoR2[2WmIHL5JIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? MVmyOFk2OzV4MR?=
HepG2 MmjnSpVv[3Srb36gRZN{[Xl? MWqxNFAhdk1? MWKwMlUhcA>? MlrhSG1UVw>? MlnrZoxw[2u|IF3BMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=> MlnqNlQ5PjN|NUC=
A549  MmW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3IWI4{KML3TdMg MXWyJIg> Mlrnd5VxeHKnc4Pld{Bx\W2ndILlfIVlNWmwZIXj[YQhSWu2IHHu[EBIW0t|zsKgZYN1cX[jdHnvckwhWy2yaHHz[UBienKnc4SsJINmdGxiYYDvdJRwe2m|IHHu[EBk[XOyYYPlMVMh[WO2aY\heIlwdg>? M3HCT|I1QDR5OE[z
A549  NI\QfVdHfW6ldHnvckBCe3OjeR?= M3\le|ExyqEQvH5CpC=> MnLsNVYhcA>? NFyxUW9FVVOR M37rXY1w\HWuYYTld{B1cGViSVHWJJJmeGyrY3H0bY9vKGGwZDDjZZV{\XNicnX0[Y51cW:wIH;mJG5RKGmwIITo[UBvfWOuZYXzMi=> MXGyOFgxOjFzMR?=
SK-N-LO MVfGeY5kfGmxbjDBd5NigQ>? NWPzSpBVOTByIH7N MmjhNE42KGh? NFrTNHRl\WO{ZXHz[ZMhfGinIIP0bY12dGGwdDDl[oZm[3S|IH;mJI1wenCqaX7lJI9vKEGtdDDwbI9{eGixconsZZRqd25? M3:2O|I1PjV2NkC2
HL-60 NX3xOHNRTnWwY4Tpc44hSXO|YYm= MX[wMlHDqM7:TR?= NX7tNnkxPzJiaB?= MV\icI9kc3NiZHHzZZRqdmmkLXnu[JVk\WRiY3XscEBlcW[oZYLlcpRq[XSrb36= NEnL[WYzPDZyN{K3Ny=>
HepG2  NH6ydVRHfW6ldHnvckBCe3OjeR?= NULrZ2x4OjByIH7N NFz2To8xNjViaB?= M{SxbIF1fGWwdXH0[ZMhTm:6TzDwbI9{eGixconsZZRqd25? Ml;XNlQ2OzVzOUK=
H520 M{PP[2Z2dmO2aX;uJGF{e2G7 NY\kRph6OTEEoN88US=> NWrwNYVrOSCq MVTEUXNQ MnPE[IVkemWjc3XzJINmdGy3bHHyJJBpd3OyaH:tRWtVKHC{b4TlbY4hdGW4ZXzz MknwNlQ1PDd7M{W=
H1975 NH7kUoVHfW6ldHnvckBCe3OjeR?= MlrhNVDDqM7:TR?= NYHG[5BtOSCq NWC1Vmp2TE2VTx?= NH7ueYRl\WO{ZXHz[ZMh[2WubIXsZZIheGixc4Doc{1CU1RicILveIVqdiCuZY\lcJM> NX3wRXdxOjR2NEe5N|U>
MG-63 MVPBdI9xfG:|aYOgRZN{[Xl? MorZNVAhyrWP M4Ww[FEzKGh? NGjmdGRmdmijbnPld{BFWC2rbnT1Z4VlKGGyb4D0c5Nqew>? NGe5[mMzPDN3OEOwNS=>
5637 MnjkRZBweHSxc3nzJGF{e2G7 NFOzOYsyOMLizszN NGm5RXQ1OCCvaX6= Ml[5doV3\XK|ZYOgdFIyX0GIMTDlfJBz\XO|aX;uMEBETEtiZYjwdoV{e2mxbjygZY5lKGOnbHygbY5pcWKrdHnvckBqdmS3Y3XkJIJ6KG[3Y3;p[IFv Ml;sNlQ{OzN6Nki=
HEK-293 NHHFUINHfW6ldHnvckBCe3OjeR?= Ml7RNVUxdk1? NYPoRlJXOTZiaB?= MoPPSG1UVw>? M3rKO4Rm[3KnYYPld{BEWlRiYXP0bZZqfHl? MUCyOFMzPDN4Nh?=
SW480  MlHYSpVv[3Srb36gRZN{[Xl? NVXNXI1uOTVybl2= M1n4TlIxKGh? M2HjZWROW09? MXjy[YR2[2W|IHPlcIx2dGG{IHHjZ5VufWyjdHnvckBw\iEQsj3jZZRmdmmw M1P3NVI1OzJ2M{[2
HepG2 M{LZe2Z2dmO2aX;uJGF{e2G7 NUDLPXdwOTByIH7N M1H5UlI1KGh? MWLheJRmdnWjdHXzJJRp\SClb3zvcolmeyCxZjD0bIUhfHWvb4KgZ4VtdHNid3n0bEB2eHKnZ4XsZZRqd25ib3[gRYt1OQ>? MYCyOFI6PzVzMB?=
HCT 116  M4PMdmZ2dmO2aX;uJGF{e2G7 NYHWR2NXOTByIH7N MYeyOEBp MV7heJRmdnWjdHXzJJRp\SClb3zvcolmeyCxZjD0bIUhfHWvb4KgZ4VtdHNid3n0bEB2eHKnZ4XsZZRqd25ib3[gRYt1OQ>? MWCyOFI6PzVzMB?=
BEL/FU NUjvSHp4TnWwY4Tpc44hSXO|YYm= Mo\4NUBuVQ>? M{\RZlI1KGh? MXvk[YNz\WG|ZYOgdJJwfGWrbjDs[ZZmdHNib3[geIhmKFCLM1uvRYt1KHCjdHj3ZZk> MWiyOFI{OjB7OR?=
Huh7  M3PkZWZ2dmO2aX;uJGF{e2G7 NXGzZ2RFO8LizszN M3n1UlEhcA>? MUPy[YR2[2W|IITo[UB3cXK3czDlcpRzgSCrboTvJJRp\SClZXzsdy=> MXWyOFE5PDF7Nh?=
A-375 MlXvRZBweHSxc3nzJGF{e2G7 MX:0M|gh|ryP NH\sV3AzPCCq M1zBNoVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= MYKyOFEyOzF5Mx?=
A-375-TS  NYfGUZFnSXCxcITvd4l{KEG|c3H5 NIPtPVA1NzhizszN NF7sWnAzPCCq MX7lcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li MkHzNlQyOTNzN{O=
Mel-HO NYPVU|Q{SXCxcITvd4l{KEG|c3H5 MUG0M|gh|ryP Mmj4NlQhcA>? Mm\x[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= MWSyOFEyOzF5Mx?=
Mel-HO-TS Mkf6RZBweHSxc3nzJGF{e2G7 MVq0M|gh|ryP MYOyOEBp MnHF[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= M{XyZVI1OTF|MUez
MeWo NIK5T|ZCeG:ydH;zbZMhSXO|YYm= MlSzOE85KM7:TR?= MUSyOEBp NH:x[YlmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg NILOVlgzPDFzM{G3Ny=>
Mel-2a M1;OPGFxd3C2b4Ppd{BCe3OjeR?= M4\6VVQwQCEQvF2= M2X3[FI1KGh? NUDqZYJ5\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> MkHzNlQyOTNzN{O=
MDA-MB-231 Mn7ZSpVv[3Srb36gRZN{[Xl? NFzTXIsx6oDVNECwJI5O M3POUVQhcA>? Mkfod5VxeHKnc4Pld{BCc3RicHjvd5Bpd3K7bHH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUWyNlkxPjJ3OR?=
MDA-MB-231 MUTGeY5kfGmxbjDBd5NigQ>? M2nLRVQxOCCwTR?= NIrQdYw1KGh? MnrX[IVkemWjc3XzJG1OWC17IHHu[EBKVC16IIDyc5RmcW5iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NE\6fm0zOjlyNkK1PS=>
Jurkat MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7wZnMxNjJ3LUGuNlUh|ryP NGHOXoIzPC92ODDo NX;mb4lHTE2VTx?= NHnQbYFqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= MXqxPVc2PzF6NR?=
Namalwa M3HVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn4NE4zPS1zLkK1JO69VQ>? NV;WbnJyOjRxNEigbC=> NYruXmw6TE2VTx?= NUfrO5gxcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= NYCzTmVlOTl5NUexPFU>
Jurkat MmPNRZBweHSxc3nzJGF{e2G7 M3jOelAvOjVvMT6yOUDPxE1? MX6yOE81QCCq NH\kWW5FVVOR MlTQbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy M1PXTlE6PzV5MUi1
Namalwa NWnlWHh6SXCxcITvd4l{KEG|c3H5 MXGwMlI2NTFwMkWg{txO NIfYcZMzPC92ODDo NXThcGVITE2VTx?= NEDSW3hqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> NFPwSXcyQTd3N{G4OS=>
K562 MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDHNlQhcA>? MX3JR|UxRTJ3wsGwMlE1KG6P NXvoT2pYOTl4NkKzOlE>
SW1990 MWnGeY5kfGmxbjDBd5NigQ>? M3v0OVAvODFvMTFOwG0> MVqxJIg> Ml\ubY5pcWKrdIOgTGEucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v MkKyNVk1PjlyMkC=
RT112  MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TDNlExyqEQvF2= NYfZcIJnOjRiaB?= MnPkSG1UVw>? NYPlZ4Ry\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKEd{L12gZ4VtdHN? MV2xPFc5Pzh|Mh?=
MHG-U1 NXXVTZVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i0fFExyqEQvF2= MVSyOEBp M1Xw[GROW09? M3[1[oRm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBIOi:PIHPlcIx{ MYmxPFc5Pzh|Mh?=
SMMC-7721 MVfBdI9xfG:|aYOgRZN{[Xl? NVzDU|VTOjBywrDuUS=> NFzy[4kzPCCq MUXpcoNz\WG|ZYOgR2hZNWmwZIXj[YQh[XCxcITvd4l{ MkLXNVc2PTdzOUG=
SMMC-7721 MVHGeY5kfGmxbjDBd5NigQ>? MofQNlAxyqCwTR?= NUjvfGx7OjRiaB?= NXvQW3h4fXBvcnXneYxifGW|IN8yNUw1T1RzIHX4dJJme3Orb36= M1uwOVE4PTV5MUmx
HeLa MkXkSpVv[3Srb36gRZN{[Xl? MV6xNFDDqG6PwrC= NWftR3hsOSCq NX72To93[Wy2ZYLzJJRp\SCvb4LwbI9td2e7IH;mJJRp\SC2cnHud4ZmenKrbjDy[YN6[2yrbnegZ49ueGG{dH3lcpQ> NH31dVEyPjh7MEmxOS=>
MRC5VI NELrVW9HfW6ldHnvckBCe3OjeR?= NIDUbGkyOi53IH3N Mn7mNE42KGh? M1fJPWROW09? NX7lS2Fs[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? NV\JXYFnOTZ{MkezPVQ>
AT5BIVA NFP2O3hHfW6ldHnvckBCe3OjeR?= NWLBOngzOTJwNTDtUS=> MlXNNE42KGh? NF3VZndFVVOR NEDLboFi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? Ml3wNVYzOjd|OUS=
M059J M3LlT2Z2dmO2aX;uJGF{e2G7 NHOwRVQyOi53IH3N NGr5dHgxNjViaB?= MkHXSG1UVw>? NY\oPJNw[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? MV6xOlIzPzN7NB?=
HeLa MUPGeY5kfGmxbjDBd5NigQ>? MXKxNk42KG2P MnzqNE42KGh? NFfTfW1FVVOR Ml;WZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> MXWxOlIzPzN7NB?=
N2a NHnEb45CeG:ydH;zbZMhSXO|YYm= MYewMlEuOTBizszN MUOyJIg> NFWycHdqdmS3Y3XzJIRm[3KnYYPl[EBk\WyuII\pZYJqdGm2eTDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?= MnqxNVU5PDJ5Nke=
Jurkat  NGTMXY1McW6jc3WgRZN{[Xl? M{XNcWlEPTBib3[gNlQhdk1? NFG2ToMyPTZ4NEWxPS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-GSK3β / GSK3β / Bcl-xl / Bax / Caspase-3 / Cleaved caspase-3; 

PubMed: 25344912     


Four esophageal cancer cell lines were treated with different concentrations of wortmannin for 48 h, and cell lysates were collected for Western blot analysis of p-AKT, AKT, p-GSK3β, GSK3β, Bcl-xL, Bax, caspase-3, and cleaved caspase-3.

25344912
Immunofluorescence
DNMT1; 

PubMed: 24001151     


PC3 cells were treated with DMSO or wortmannin (1 μM) for 24 hours. DNMT1 and DNMT3B cellular localization was visualized by immunofluorescent staining. After 24h of treatment, cells were fixed in methanol, incubated with the indicated antibodies, stained with Alexa Fluor 594-tagged secondary antibodies and counterstained with DAPI. Slides were then mounted and examined under a fluorescence microscope. The bright field images of PC3 cells treated with DMSO or wortmannin (1 μM) for 24 hours are shown (right panel).

24001151
Growth inhibition assay
Cell viability; 

PubMed: 25344912     


MTT assay was used to determine the effects of different concentrations of wortmannin on viability of esophageal cancer cells lines KYSE150, HKESC-1, KYSE270, and T.Tn. Bars, SD; * P < 0.05; **, P < 0.01; ***, P < 0.001 compared with DMSO-treated cells.

25344912
In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
- Collapse
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420
Smiles CC(=O)OC1CC2(C(CCC2=O)C3=C1C4(C(OC(=O)C5=COC(=C54)C3=O)COC)C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID